Preclinical Study Shows Targeted Degradation of MYC and KRAS Using Bionic Biologics Platform
Why have traditional cancer treatments struggled to target the most aggressive forms of the disease? Grove Biopharma, a private biotechnology company based in Chicago, is addressing this challenge by engineering protein-like polymers (PLPs) to degrade key oncogenic drivers. The company’s Bionic Biologics platform integrates synthetic chemistry, precision polymerization, and protein engineering to create scalable, transformative therapeutics for intractable intracellular targets.
Grove Biopharma today announced the publication of preclinical results in Nature Communications, demonstrating the targeted degradation of MYC and KRAS, two key oncogenic drivers. “MYC and KRAS drive a significant portion of human cancers – often aggressive ones – and effective drugs against these targets remain extremely limited,” said Nathan Gianneschi, Ph.D., Principal Investigator on the study and Scientific Founder of Grove Biopharma. The study underscores the platform’s potential for next-generation proximity-based therapeutics in cancer.
Key Insights at a Glance
- MYC and KRAS: These oncogenic drivers are targeted by Grove Biopharma’s PLPs for degradation.
- Bionic Biologics Platform: Integrates synthetic chemistry, precision polymerization, and protein engineering.
- Preclinical Results: Published in Nature Communications, showing successful degradation of MYC and KRAS.
- Scalability and Versatility: PLPs are modular, cell-permeable, and scalable to manufacture.
Why Traditional Therapies Fall Short in Targeting Aggressive Cancers
Traditional small molecules and antibodies have struggled to target intrinsically disordered proteins like MYC and KRAS, which underlie many aggressive cancers. These proteins lack well-defined binding pockets, making them difficult to inhibit. Grove Biopharma’s Bionic Biologics platform addresses this gap by creating protein-like polymers that can engage and degrade these challenging targets. The inability to target these proteins has long been a bottleneck in cancer research, and Grove’s approach offers a promising solution.
Why the Window for Action Is Closing Fast
Just as a racecar driver must navigate a tight turn to stay ahead, Grove Biopharma is racing to develop effective treatments for aggressive cancers. The preclinical success of PLPs in degrading MYC and KRAS highlights the urgency of translating these findings into clinical applications. With the clock ticking, Grove is accelerating the development of PLPs to target a broader range of diseases, including neurodegenerative, inflammatory, and metabolic conditions. The next steps include further preclinical studies and the initiation of clinical trials.
Grove Biopharma Mobilizes for Therapeutic Development
Grove Biopharma has licensed the intellectual property for its PLP technology from Northwestern University and is rapidly advancing it toward therapeutic development. The company’s Bionic Biologics platform generates fully synthetic, rationally designed protein mimetics that overcome the limitations of conventional biologics and peptides. “Our Bionic Biologics platform generates fully synthetic, rationally designed protein mimetics that overcome the major limitations of conventional biologics and peptides,” said Paul Bertin, Ph.D., Co-Founder, President, and Chief Technology Officer at Grove Biopharma. The platform’s modular design and cell-permeability enable rapid, iterative design-build-test cycles, facilitating the identification of lead molecules for challenging intracellular targets. Grove Biopharma is poised to transform the landscape of cancer treatment by addressing previously untouchable targets.
Future Outlook
The development of PLPs by Grove Biopharma is like a new tool in a surgeon’s kit, designed to tackle the most complex and aggressive cancers. The company’s ability to degrade MYC and KRAS through targeted protein degradation represents a significant breakthrough. As Grove continues to refine and expand its Bionic Biologics platform, the potential for next-generation therapeutics in cancer and other diseases becomes increasingly clear. The company is committed to advancing PLPs to target a broader range of diseases, with a focus on scalability and manufacturability.
Conclusion
The preclinical success of Grove Biopharma’s Bionic Biologics platform in degrading MYC and KRAS underscores the company’s innovative approach to addressing the most challenging intracellular targets. By combining the selectivity of biologics with the ability to enter cells and induce protein degradation, Grove is paving the way for transformative cancer treatments. Join the conversation in the comments below.
Source link: https://www.businesswire.com/
